GSK receives FDA accelerated approval for JEMPERLI (dostarlimab-gxly) for adult patients with mismatch repair-deficient (dMMR) recurrent or advanced solid tumours
The Pharma Data
AUGUST 17, 2021
Mismatch repair-deficient tumours contain abnormalities that affect the proper repair of DNA when copied in a cell [i]. Initiate treatment with insulin as clinically indicated. Immune-Mediated Dermatologic Adverse Reactions. In the US, prevalence of dMMR across patients with solid tumours has been estimated at 14% [ii].
Let's personalize your content